Zydus Lifesciences
ZYDUSLIFE · NSE · Pharma · India
Financials at a glance
Source: Yahoo FinanceAnnual
Quarterly · last 5
Revenue (FY2026)
₹27,148 Cr
Net margin
18.6%
Revenue CAGR (3y)
+16.3%
Profit CAGR (3y)
+37.0%
Net profit (FY2026)
₹5,040 Cr
Ask MarketChacha about ZYDUSLIFE
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Financials
Yearly
| Period | Revenue | Net profit | Net margin |
|---|---|---|---|
| FY2026 | ₹27,148 Cr | ₹5,040 Cr | 18.6% |
| FY2025 | ₹23,242 Cr | ₹4,526 Cr | 19.5% |
| FY2024 | ₹19,547 Cr | ₹3,860 Cr | 19.7% |
| FY2023 | ₹17,237 Cr | ₹1,960 Cr | 11.4% |
Quarterly
| Period | Revenue | Net profit | EPS | Net margin |
|---|---|---|---|---|
| Q1 FY27 | ₹8,017 Cr | ₹990 Cr | 9.35 | 12.4% |
| Q4 FY26 | ₹7,587 Cr | ₹1,341 Cr* | 12.65 | 17.7% |
| Q3 FY26 | ₹6,865 Cr | ₹1,042 Cr | — | 15.2% |
| Q2 FY26 | ₹6,123 Cr | ₹1,259 Cr | — | 20.6% |
| Q1 FY26 | ₹6,574 Cr | ₹1,467 Cr | — | 22.3% |
* Net profit includes one-off / non-operating items (e.g. a settlement or accounting gain), so it doesn’t reflect operating performance — net margin is hidden for that period.
Figures as reported, in ₹ (crore). Source: Yahoo Finance.
Filings & announcements
2026
Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH.
BSE8/31/2026Incorporation Of A Wholly Owned Subsidiary In Gift City, Gandhinagar, Gujarat
Incorporation of a wholly owned subsidiary in Gift City, Gandhinagar, Gujarat
BSE8/26/2026Disclosure Under SEBI (Prohibition Of Insider Trading) Regulations, 2015
Disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015
BSE8/24/2026Investor Presentation
BSE8/23/2026ESG Rating
BSE8/21/2026Zydus announces final approval from the USFDA for Ascorbic Acid Injection with 180-Days CGT exclusivity.
BSE8/21/2026Shareholder Meeting / Postal Ballot-Outcome of AGM
Regulation 44(3) disclosure of AGM 2026
BSE8/11/2026materialChange in Directors
BSE8/11/2026Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Scrutinizer''s report
BSE8/11/2026materialShareholder Meeting / Postal Ballot-Outcome of AGM
Outcome of AGM
BSE8/11/2026materialReporting of violation of Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015
BSE8/11/2026Press Release
BSE8/11/2026Press Release
BSE8/11/2026Investor Presentation
BSE8/11/2026Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended On June 30, 2026
Unaudited financial results for the quarter ended on June 30, 2026
BSE8/11/2026Unaudited Financial Results For The Quarter Ended On June 30, 2026
Unaudited financial results for the quarter ended on June 30, 2026
BSE8/11/2026Receipt Of Order From The Office Of The Superintendent Of Stamps, Gandhinagar, Gujarat
Receipt of order from the Office of the Superintendent of Stamps, Gandhinagar, Gujarat.
BSE7/29/2026Strikes /Lockouts / Disturbances
Disruption of operations due to heavy rain and water logging
BSE7/25/2026Zydus receives approval for Phase III trial of Desidustat in patients with Sickle Cell Disease, to be conducted in collaboration with ICMR.
BSE7/23/2026
In the news
- Zydus Lifesciences Share Price News After 2.11% DeclineUnivest · 8/31/2026
- Pharma stocks fall today, August 31: Wockhardt declines 3.78%, Zydus Lifesciences down 2.15%, Glenmark Pharma falls 1.87%Business Upturn · 8/31/2026
- Zydus Lifesciences share price: should you Buy, Sell or Hold when two brokerages say sell and one says buy?Business Upturn · 8/31/2026
- Zydus FY26 net profit rises 11.4%; dividend announcedscanx.trade · 8/30/2026
- Zydus Lifesciences Ltd. Key Financial Ratios – Valuation, Profitability & MoreValue Research · 8/28/2026
- Zydus Lifesciences Share Price: price rise and valuationUnivest · 8/27/2026
- Zydus Lifesciences Ltd rises for third consecutive sessionBusiness Standard · 8/27/2026
- 4 Undervalued Pharmaceutical Stocks Trading Below Fair ValueUnivest · 8/27/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.